'Professional Use' Immunochromatographic assay kit for qualitatively and simultaneously detecting the antigens of influenza virus (type A and B) and SARS-CoV-2 in nasopharyngeal swab from human
MFDS approval
CE mark
Getting results In 20 minutes
Simple and easy to use
Optimized for Point of Care with a small diagnostic kit
No need to use extra reader
High diagnostic accuracy
Economical and capable of mass testing
The COVID-19 disease caused by SARS-CoV-2 is a new respiratory epidemic and was declared "pandemic" by the World Health Organization (WHO), the World Health Organization, in March 2020. Symptoms of this epidemic vary, but are mainly fatigue, high fever, cough, and in more severe cases, breathing problems and severe lung damage. Although molecular diagnostics are the standard diagnostic method for COVID-19, rapid antigen testing, which is simple, convenient, and ready to be tested in the field, has been widely used in quarantine in most developed countries, including the United States, Japan, and Europe, due to various constraints (dependence on accuracy by gene extraction technology, longer than six hours of analysis, expensive analytical equipment, and highly trained professionals). GenBody COVID-19 Ag (GenBody COVID-19 Ag) product is a rapid immunoassay method that diagnoses the antigen of the SARS COVID 2 virus that causes COVID-19 disease in a qualitative way using samples collected using cotton swabs from human nasopharynx and nasopharynx.
Influenza is an acute respiratory disease caused by a virus. Influenza is often divided into types A, B, and C, and influenza viruses found mostly in patients are type A or type B. GenBody Influenza A/B Ag is an in vitro diagnostic reagent that can quickly detect influenza A and B virus antigens present in human nasopharyngeal feces using immunochromatography. The measurement principle is that specific antibodies to influenza virus antigens are bound to gold particles, and specific antibodies to influenza virus antigens are bound to the test line of the membrane. Conjugates react first with influenza virus antigens collected from nasal pharyngeal secretions to form an antigen-antibody complex, which travels as it spreads to the membrane by capillary action. On the way, a secondary antigen-antibody reaction takes place with a specific antibody against the influenza virus antigen bound to the membrane in advance, indicating a visible red line to determine the result.